## ALGN: Align Technology, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.95 indicates fundamental undervaluation. Caution: overbought RSI (73).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($147.41)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. Align Technology stock gains as competitor raises prices**
- Source: Investing.com | 20251205T190759 | Bullish | Relevance: 100%
- Align Technology (NASDAQ:ALGN) received a reiterated Buy rating and $200.00 price target from Stifel following news of a competitor's price increase. Angelalign is set to raise prices on its clear aligner offering by 8-9% effective January 1st in the U.S., which could benefit Align Technology's market position, especially with its upcoming zero refinement plan. Stifel noted that a significant percentage of practices are more likely to return cases to Align Technology due to this new plan.

**2. Is Align Technology (ALGN) Quietly Recasting Its Moat Around AI-Driven End-to-End Dental Workflows?**
- Source: Simply Wall Street | 20251204T200756 | Somewhat-Bullish | Relevance: 100%
- Align Technology (ALGN) is enhancing its digital dentistry platform with AI-driven tools, faster scanners like the iTero Lumina, and integrated software to create end-to-end dental workflows. This strategic push aims to deepen digital workflow adoption, although the company faces challenges with softer case starts and pricing pressure. The article suggests this technological advancement could influence Align's investment narrative, with analysts projecting significant revenue and earnings growth by 2028.

**3. Align Technology Showcases Digital Dentistry Innovations at Greater New York Dental Meeting 2025**
- Source: Business Wire | 20251204T090919 | Bullish | Relevance: 100%
- Align Technology highlighted its latest innovations in digital dentistry at the Greater New York Dental Meeting 2025, showcasing advancements across its Align™ Digital Platform. Key features included the iTero Lumina™ scanner, Align™ Oral Health Suite, Invisalign Smile Architect™, iTero™ Design Suite, and ClinCheck® Signature experience, alongside educational sessions from industry experts. The company emphasized how these innovations enhance treatment planning, practice workflows, and patient experiences for dental professionals.

**4. Align Technology Showcases Digital Dentistry Innovations at Greater New York Dental Meeting 2025**
- Source: Morningstar | 20251203T205500 | Bullish | Relevance: 100%
- Align Technology (NASDAQ: ALGN) showcased its latest digital dentistry innovations at the Greater New York Dental Meeting 2025, highlighting advancements in its Align™ Digital Platform. Key innovations presented included the iTero Lumina™ scanner, Align™ Oral Health Suite, Invisalign Smile Architect™, iTero™ Design Suite, and ClinCheck® Signature experience, designed to enhance clinical outcomes and patient treatment. The company also sponsored clinical education sessions led by industry experts, emphasizing its commitment to advancing digital dentistry.

**5. Align Technology (NASDAQ: ALGN) spotlights iTero, exocad, Invisalign at GNYDM 2025**
- Source: Stock Titan | 20251203T205500 | Bullish | Relevance: 100%
- Align Technology showcased its latest digital dentistry innovations at the Greater New York Dental Meeting (GNYDM) 2025, highlighting advancements across its Align Digital Platform, including the Invisalign system, iTero intraoral scanners, and exocad CAD/CAM software. The company featured new products like the iTero Lumina scanner and Invisalign Smile Architect, alongside educational sessions for dental professionals. These innovations aim to enhance treatment planning, practice efficiency, and patient outcomes for dental practices worldwide.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.6% (+0.7%)
- Blackrock Inc.: 6.9% (-3.4%)
- Ninety One UK Ltd: 6.3% (+136.6%)
- Capital Internationa: 4.2% (+88.6%)
- State Street Corpora: 4.0% (-1.3%)

### Key Risks

1. High beta (1.86) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +3.2% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.95 indicates undervaluation relative to growth. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.5B |
| Beta | 1.86 |
| 52W Range | $122.00 - $237.23 |
| Short Interest | 5.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.95 |
| Forward P/E | 14.4 |
| Current P/E | 15.4 |
| YoY Growth | 7.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 4.2% to 7.4% (+3.2% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 91st percentile. MRS_5 at 2.0% confirms short-term momentum alignment. AM_20 at 9.9% shows strong absolute momentum above own 20MA. Outperforming sector by 9.7pp, stock-specific strength. Below SMA200 (0.98x), long-term trend not supportive. MACD histogram positive (1.73), confirming momentum. RSI overbought at 73, risk of mean reversion. OFD pattern: -SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 7.43% (CS: 92) | Strong |
| RSI_14 | 73.3 | Overbought |
| MACD Histogram | 1.73 | Bullish |
| vs SMA20 | 1.099x | Above |
| vs SMA50 | 1.151x | Above |
| vs SMA200 | 0.980x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $157.21
- **Stop Loss:** $147.41 (6.2% risk)
- **Target:** $176.81 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 51
- **Position Value:** $8,017.71
- **Portfolio %:** 8.02%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-04 (Est: $2.96)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.41 | $2.61 | +8.4% |
| 2025Q2 | $2.57 | $2.49 | -3.3% |
| 2025Q1 | $1.99 | $2.13 | +7.1% |
| 2024Q4 | $2.45 | $2.44 | -0.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*